HK1142345A1 - Bis-met histones - Google Patents
Bis-met histonesInfo
- Publication number
- HK1142345A1 HK1142345A1 HK10108890.2A HK10108890A HK1142345A1 HK 1142345 A1 HK1142345 A1 HK 1142345A1 HK 10108890 A HK10108890 A HK 10108890A HK 1142345 A1 HK1142345 A1 HK 1142345A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nucleic acid
- acid molecule
- present
- polypeptide
- relates
- Prior art date
Links
- 108010033040 Histones Proteins 0.000 title abstract 2
- 102000006947 Histones Human genes 0.000 title 1
- USBHFGNOYVOTON-UHFFFAOYSA-K bis(dimethylcarbamothioylsulfanyl)bismuthanyl n,n-dimethylcarbamodithioate Chemical compound [Bi+3].CN(C)C([S-])=S.CN(C)C([S-])=S.CN(C)C([S-])=S USBHFGNOYVOTON-UHFFFAOYSA-K 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 238000010998 test method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07007200A EP1985628A1 (en) | 2007-04-05 | 2007-04-05 | Bis-met histones |
| EP07018956 | 2007-09-26 | ||
| PCT/EP2008/002746 WO2008122434A1 (en) | 2007-04-05 | 2008-04-07 | Bis-met histones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1142345A1 true HK1142345A1 (en) | 2010-12-03 |
Family
ID=39645600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10108890.2A HK1142345A1 (en) | 2007-04-05 | 2010-09-19 | Bis-met histones |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9409960B2 (ru) |
| EP (1) | EP2142563B1 (ru) |
| JP (2) | JP5634259B2 (ru) |
| KR (2) | KR101583592B1 (ru) |
| CN (1) | CN101679498B (ru) |
| AT (1) | ATE517118T1 (ru) |
| CA (1) | CA2682887C (ru) |
| ES (1) | ES2372998T3 (ru) |
| HK (1) | HK1142345A1 (ru) |
| RU (2) | RU2640247C2 (ru) |
| WO (1) | WO2008122434A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682887C (en) | 2007-04-05 | 2015-07-14 | Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh | Bis-met histones |
| RU2634266C2 (ru) * | 2011-12-07 | 2017-10-24 | Белджиан Волишн Спрл | Способ детекции аддуктов нуклеосом |
| RU2478711C1 (ru) * | 2011-12-19 | 2013-04-10 | Открытое акционерное общество "Институт стволовых клеток человека" | Способ повышения эффективности вирусной трансдукции |
| RU2539913C2 (ru) * | 2013-05-15 | 2015-01-27 | Общество с ограниченной ответственностью "РД-БИОТЕХ" | Вакцина для профилактики и лечения ротавирусной инфекции, содержащая гибридный белок в качестве активного агента (варианты) |
| KR102208814B1 (ko) | 2014-03-28 | 2021-01-28 | 삼성전자주식회사 | 통신 시스템에서 패킷 송수신 방법 및 장치 |
| RU2634408C1 (ru) * | 2016-10-03 | 2017-10-26 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ получения активной фармацевтической субстанции рекомбинантного бисметионилгистона Н1.3 |
| RU2669937C1 (ru) * | 2017-10-17 | 2018-10-17 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Фармацевтическая противоопухолевая композиция паклитаксела с гистоном Н1.3 в качестве носителя и способ получения композиции |
| WO2019233842A1 (en) | 2018-06-08 | 2019-12-12 | F. Hoffmann-La Roche Ag | Peptidic linker with reduced post-translational modification |
| JP1671757S (ru) * | 2020-02-26 | 2020-11-02 | ||
| JP1671845S (ru) * | 2020-02-26 | 2020-11-02 | ||
| CN112480234B (zh) * | 2020-12-14 | 2022-10-04 | 上海交通大学 | 一种生物活性肽aaggydveknnsriklglk及其制备方法和应用 |
| WO2023126672A1 (en) | 2021-12-27 | 2023-07-06 | Santersus Ag | Method and device for removal of circulating cell free dna |
| CN117904196B (zh) * | 2024-01-05 | 2024-07-12 | 安徽大学 | 一种非小细胞肺癌组蛋白h1.4赖氨酸乙酰化点突变细胞模型的构建及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU627147B2 (en) * | 1986-10-22 | 1992-08-20 | Peter Alestrom | Production of human parathyroid hormone from microorganisms |
| US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| DE4318402A1 (de) * | 1993-06-03 | 1994-12-08 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis eines programmierten oder induzierten Zelltods eukaryontischer Zeller |
| DE10001113A1 (de) * | 2000-01-13 | 2001-07-26 | Strathmann Ag & Co | Rekombinante Herstellung von humanen Histon 1-Subtypen sowie deren Verwendung für therapeutische Zwecke |
| NZ521564A (en) * | 2000-04-12 | 2004-06-25 | Implyx Ltd | Compositions for drug delivery |
| CA2682887C (en) | 2007-04-05 | 2015-07-14 | Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh | Bis-met histones |
-
2008
- 2008-04-07 CA CA2682887A patent/CA2682887C/en not_active Expired - Fee Related
- 2008-04-07 RU RU2013137466A patent/RU2640247C2/ru active
- 2008-04-07 CN CN2008800148942A patent/CN101679498B/zh active Active
- 2008-04-07 KR KR1020137033513A patent/KR101583592B1/ko active IP Right Grant
- 2008-04-07 ES ES08735066T patent/ES2372998T3/es active Active
- 2008-04-07 KR KR1020097023198A patent/KR101468055B1/ko active IP Right Grant
- 2008-04-07 US US12/594,664 patent/US9409960B2/en active Active
- 2008-04-07 RU RU2009140759/10A patent/RU2498997C2/ru active IP Right Revival
- 2008-04-07 WO PCT/EP2008/002746 patent/WO2008122434A1/en active Application Filing
- 2008-04-07 AT AT08735066T patent/ATE517118T1/de not_active IP Right Cessation
- 2008-04-07 EP EP08735066A patent/EP2142563B1/en active Active
- 2008-04-07 JP JP2010501447A patent/JP5634259B2/ja active Active
-
2010
- 2010-09-19 HK HK10108890.2A patent/HK1142345A1/xx not_active IP Right Cessation
-
2014
- 2014-05-27 JP JP2014109023A patent/JP6073831B2/ja active Active
-
2016
- 2016-01-19 US US15/001,214 patent/US9790259B2/en active Active
- 2016-01-19 US US15/001,154 patent/US9796767B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2372998T3 (es) | 2012-01-30 |
| EP2142563B1 (en) | 2011-07-20 |
| JP6073831B2 (ja) | 2017-02-01 |
| KR20140004259A (ko) | 2014-01-10 |
| ATE517118T1 (de) | 2011-08-15 |
| US9790259B2 (en) | 2017-10-17 |
| RU2009140759A (ru) | 2011-05-10 |
| US20160130312A1 (en) | 2016-05-12 |
| KR20100016282A (ko) | 2010-02-12 |
| CN101679498B (zh) | 2013-07-31 |
| JP5634259B2 (ja) | 2014-12-03 |
| US20160130313A1 (en) | 2016-05-12 |
| JP2010523093A (ja) | 2010-07-15 |
| CN101679498A (zh) | 2010-03-24 |
| EP2142563A1 (en) | 2010-01-13 |
| WO2008122434A1 (en) | 2008-10-16 |
| WO2008122434A8 (en) | 2010-10-21 |
| US9409960B2 (en) | 2016-08-09 |
| KR101583592B1 (ko) | 2016-01-12 |
| RU2013137466A (ru) | 2015-02-20 |
| US20110034370A1 (en) | 2011-02-10 |
| CA2682887A1 (en) | 2008-10-16 |
| US9796767B2 (en) | 2017-10-24 |
| CA2682887C (en) | 2015-07-14 |
| RU2498997C2 (ru) | 2013-11-20 |
| JP2014209909A (ja) | 2014-11-13 |
| KR101468055B1 (ko) | 2014-12-02 |
| RU2640247C2 (ru) | 2017-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1142345A1 (en) | Bis-met histones | |
| HRP20190689T1 (hr) | Muteini suznog lipokalina koji vežu il-4r alfa | |
| EP2557090A3 (en) | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
| WO2008074867A3 (en) | Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use | |
| WO2011036445A3 (en) | Polypeptides and uses thereof | |
| MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
| NO20092774L (no) | HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette | |
| MX2010005783A (es) | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. | |
| WO2008043822A3 (en) | Amino acid sequences that bind to a desired molecule in a conditional manner | |
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| MX2011008094A (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
| EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| EP3461844A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders | |
| WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| WO2009149171A4 (en) | Fgf21 mutants and uses thereof | |
| PL1888641T3 (pl) | Białka wiążące albuminę surowicy | |
| MX338914B (es) | Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. | |
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
| WO2008057463A3 (en) | Peptide-based conditioners | |
| JP2016519051A5 (ru) | ||
| WO2009081374A3 (en) | Cosmetic use of plakoglobin-type proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200402 |